CTTH Company Profile and Key Details

Dividend and splits history remains an important factor for investors monitoring long-term returns.

The stock is currently mid-range between its 52-week high and low $0.04 and $0.10. With a market capitalization of about $3.02 million, CTT Pharmaceutical Holdings, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.77). Key stats such as the average daily volume over the past year has been around 25.71 thousand shares, trading with heavier-than-usual volume. Headquartered in Tampa, FL, CTT Pharmaceutical Holdings, Inc. operates in the Healthcare sector and the Medical - Pharmaceuticals industry. Led by CEO Ryan Khouri, the company employs approximately 1 people and listed since April 18, 1997. CTT Pharmaceutical Holdings, Inc. engages in the development of oral drug delivery systems for pain management and treatment.

CTT Pharmaceutical Holdings, Inc. trades at a P/E ratio of -18.89, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 116.95 reflecting a rich premium to book value. The P/FCF stands at -48.23, also below market averages. Compared to sector medians, CTT Pharmaceutical Holdings, Inc. P/S is trading at a discount to the sector, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Valuation shows CTT Pharmaceutical Holdings, Inc. trading at a premium to the broader market with a P/E of -18.89.

Our AI price prediction model suggests that CTT Pharmaceutical Holdings, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term.